CN102159222B - 生物活性剂,药物,化妆品,保鲜剂,以及植物以及动物的发育促进剂 - Google Patents
生物活性剂,药物,化妆品,保鲜剂,以及植物以及动物的发育促进剂 Download PDFInfo
- Publication number
- CN102159222B CN102159222B CN200980148974.1A CN200980148974A CN102159222B CN 102159222 B CN102159222 B CN 102159222B CN 200980148974 A CN200980148974 A CN 200980148974A CN 102159222 B CN102159222 B CN 102159222B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- bioactivator
- salt
- agent
- iron salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 10
- 230000012010 growth Effects 0.000 title claims abstract description 8
- 239000002537 cosmetic Substances 0.000 title claims description 8
- 239000012867 bioactive agent Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 150000002505 iron Chemical class 0.000 claims abstract description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940088594 vitamin Drugs 0.000 claims abstract description 21
- 229930003231 vitamin Natural products 0.000 claims abstract description 21
- 235000013343 vitamin Nutrition 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 21
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 15
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 15
- 239000011718 vitamin C Substances 0.000 claims abstract description 15
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 12
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 12
- 239000011712 vitamin K Substances 0.000 claims abstract description 12
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 12
- 229940046010 vitamin k Drugs 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 9
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 235000006708 antioxidants Nutrition 0.000 abstract description 3
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 150000008065 acid anhydrides Chemical class 0.000 description 20
- 239000011550 stock solution Substances 0.000 description 19
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 235000019688 fish Nutrition 0.000 description 11
- 241000251468 Actinopterygii Species 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- -1 iron salt Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 229940087168 alpha tocopherol Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- 239000002076 α-tocopherol Substances 0.000 description 5
- 235000004835 α-tocopherol Nutrition 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 241000269978 Pleuronectiformes Species 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000011772 phylloquinone Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- PZZKGQBMBVYPGR-UHFFFAOYSA-N η-tocopherol Chemical compound OC1=C(C)C=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 PZZKGQBMBVYPGR-UHFFFAOYSA-N 0.000 description 2
- QUEDXNHFTDJVIY-WENCSYSZSA-N (2s)-2,7,8-trimethyl-2-[(4s,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=C(C)C(C)=C2O[C@](CCC[C@@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-WENCSYSZSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- JXPHLUCMHXXHEJ-UHFFFAOYSA-N 2-(aminomethyl)-4-bromoaniline Chemical compound NCC1=CC(Br)=CC=C1N JXPHLUCMHXXHEJ-UHFFFAOYSA-N 0.000 description 1
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- UVNKIYPMUDFRGV-UHFFFAOYSA-N [Mg].C(CC)(=O)O Chemical compound [Mg].C(CC)(=O)O UVNKIYPMUDFRGV-UHFFFAOYSA-N 0.000 description 1
- MCDLETWIOVSGJT-UHFFFAOYSA-N acetic acid;iron Chemical compound [Fe].CC(O)=O.CC(O)=O MCDLETWIOVSGJT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- UHNWOJJPXCYKCG-UHFFFAOYSA-L magnesium oxalate Chemical compound [Mg+2].[O-]C(=O)C([O-])=O UHNWOJJPXCYKCG-UHFFFAOYSA-L 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- GMDNUWQNDQDBNQ-UHFFFAOYSA-L magnesium;diformate Chemical compound [Mg+2].[O-]C=O.[O-]C=O GMDNUWQNDQDBNQ-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B4/00—General methods for preserving meat, sausages, fish or fish products
- A23B4/14—Preserving with chemicals not covered by groups A23B4/02 or A23B4/12
- A23B4/18—Preserving with chemicals not covered by groups A23B4/02 or A23B4/12 in the form of liquids or solids
- A23B4/20—Organic compounds; Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B4/00—General methods for preserving meat, sausages, fish or fish products
- A23B4/14—Preserving with chemicals not covered by groups A23B4/02 or A23B4/12
- A23B4/18—Preserving with chemicals not covered by groups A23B4/02 or A23B4/12 in the form of liquids or solids
- A23B4/24—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B7/00—Preservation or chemical ripening of fruit or vegetables
- A23B7/14—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10
- A23B7/153—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10 in the form of liquids or solids
- A23B7/154—Organic compounds; Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B7/00—Preservation or chemical ripening of fruit or vegetables
- A23B7/14—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10
- A23B7/153—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10 in the form of liquids or solids
- A23B7/157—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
Abstract
本发明提供一种增强二价铁盐具有的生物活性效果且使其稳定化,并用作药物,动植物发育促进剂等的生物活性剂。其是在二价铁盐中添加作为抗氧化剂兼生物活性作用增强剂的维生素C、维生素E、维生素K之中的一种或二种以上的维生素类,并再添加作为稳定剂的镁盐。
Description
技术领域
本发明涉及一种用作药物,化妆品,保鲜剂,动物以及植物发育促进剂的生物活性剂。
背景技术
例如,二价铁盐,三价铁盐,二价三价铁盐等铁盐具有生物活性,从以往而言,已知对药物、化妆品、保鲜剂、动物和植物发育促进剂等有用。例如含有二价三价铁盐的水作为π-水为众所周知。
[专利文献1]日本特开2002-80376号公报
但是,上述铁盐易氧化,并且该铁盐的生物活性不稳定,具有长期保存而效力下降的问题。
发明内容
本发明作为解决上述以往课题的方法,而提供一种生物活性剂,其是选择该铁盐中生物活性效果最大的二价铁盐,并添加从维生素C、维生素E或维生素K中所选的一种或二种以上的维生素类作为该二价铁盐的抗氧化剂兼生物活性增强剂,并再添加镁盐作为该二价铁盐的稳定剂。
该二价铁盐和该维生素类优选为1∶1~1∶106摩尔比混合,且该二价铁盐和该镁盐优选为1∶1~1∶106摩尔比混合。
本发明再提供一种由上述生物活性剂所成的用于治疗糖尿病、高血压、癌症、肝炎、风湿病或特应性皮炎的药物。
发明的功效
本发明中,因通过具有抗氧化性的维生素C、E、K防止用作生物活性剂的二价铁盐的氧化并同时增强生物活性,并再通过镁盐使上述所增强的生物活性稳定化,从而获得能够长期保存的药物,化妆品,保鲜剂,动植物发育促进剂等。
具体实施方式
以下,详细说明本发明。
(二价铁盐)
作为本发明的生物活性剂所使用的二价铁盐,可例举如:二价铁的盐酸盐,硫酸盐,硝酸盐,磷酸盐等无机酸盐,或者是二价铁的醋酸盐,甲酸盐,草酸盐,柠檬酸盐,乳酸盐,丁酸盐,丁二酸盐,丙酸盐等有机酸盐。上述二价铁盐也可以两种以上混合使用。
(维生素类)
本发明中,作为该铁盐的抗氧化剂所使用的维生素类,是指维生素C、维生素E、维生素K。
维生素C,是L-抗坏血酸(L-ascorbinic acid),本发明中,也可使用L-抗坏血酸的碱性金属盐。特别优选的L-抗坏血酸碱性盐为L-抗坏血酸钾盐。本发明中,将L-抗坏血酸和L-抗坏血酸钾盐混合在一起称作维生素C。
维生素E,是生育酚(tocopherol),该生育酚中包含α-生育酚,β-生育酚,γ生育酚,δ生育酚,ε生育酚,ζ生育酚,η生育酚等,但α-生育酚的效力最大。
维生素K包含叶绿醌(phylloquinone,维生素K1),menaquinone(维生素K2),menadione(维生素K3)等。
上述维生素类也可两种以上一起并用。上述维生素类中,最优选为二价铁盐的抗氧化效果和生物活性增强效果最大的维生素C。
(镁盐)
本发明中所使用的镁盐是指包含;氯化镁,硫酸镁,磷酸镁,硝酸镁等镁的无机酸盐,醋酸镁,丁酸镁,甲酸镁,草酸镁,柠檬酸镁,丙酸镁等镁的有机酸盐。
上述镁盐也可两种以上并用。
为了使上述二价铁盐的生物活性稳定化,上述镁盐优选以和上述二价铁盐等摩尔或等摩尔以上添加,但上述镁盐如以相对上述1摩尔二价铁盐超过106摩尔的量添加时,为了使上述镁盐均匀地溶解在水中则必须要过量的水,其结果是本发明的上述二价铁盐的浓度变低。
(调配)
上述铁盐和上述镁盐,通常调制为水溶液,脂溶性维生素的维生素E,维生素K,分散乳化在已添加界面活性剂的水中并调制为乳胶或乳液。上述水溶液或乳胶或乳液中,上述二价铁盐和上述维生素类通常以1∶1~1∶106摩尔比混合,优先为1∶1~1∶104摩尔比混合,更优先为1∶1~1∶102摩尔比混合,上述二价铁盐和上述镁盐通常以1∶1~1∶106摩尔比混合。
为了使相对上述二价铁盐的抗氧化效果显著,上述维生素类以优选添加为和上述二价铁盐等摩尔或等摩尔以上,但上述维生素类相对1摩尔上述二价铁盐如以超出106摩尔的量添加时,则很难使上述维生素类均匀地溶解或分散在本发明的生物活性剂中,并且有可能对上述二价铁盐的生物活性带来不良影响。
在上述水溶液或乳液中,也可再添加维生素C,E,K以外的维生素,激素,油脂,润湿剂,香料,甜味料等。
本发明的生物活性剂作为药物或者动物的发育促进剂,给予人或动物的时候主要是口服,或者是照原样混合在食物中一起给予,但也可以注射,点滴或者经皮给予。
本发明的生物活性剂特别是对癌症,糖尿病,肝炎,肾炎,肾衰竭,胃和十二指肠等的溃疡,高血压,胶原病,特应性皮炎或花粉症等过敏性疾病,生理病,便秘等有治疗和预防作用,并且也可用作抗菌剂。
再有本发明的生物活性剂因不但对皮炎有治疗和预防作用,而且也具有美化皮肤作用,所以还可用作化妆品,而且还有促进动植物的发育或改良味觉的作用。
[实施例1](生物活性剂1的调制)
将0.5摩尔FeCl2脱水物(酐),和2.5摩尔维生素C(L-抗坏血酸钾盐),和3摩尔MgCl2脱水物(酐)溶解在水中并设定为1升,再将此水溶液稀释100倍从而调制成生物活性剂1的原液。
[实施例2](生物活性剂2的调制)
将5质量%的α-生育酚分散在已溶解有1质量%的脂肪酸甘油二酯的水中而调制成维生素E水性乳胶。
将上述水性溶胶以其α-生育酚达到60摩尔的量添加在溶解有0.3摩尔的FeSO4脱水物(酐),和30摩尔的MgCl2脱水物(酐)的水溶液中,并用水将总量调节至1升,再将此水溶液稀释100倍从而调制成生物活性剂2的原液。
[实施例3](生物活性剂3的调制)
将5质量%的维生素K3分散在已溶解有1.5质量%的山梨聚糖脂肪酸酯的水溶液中而调制成维生素K3水性乳胶。
将上述溶胶以其维生素K3达到108摩尔的量添加在溶解有0.27摩尔FeCl2脱水物(酐),和54摩尔MgSO4脱水物(酐)的水溶液中,并用水将总量调节至1升,再将此水溶液稀释100倍从而调制成生物活性剂3的原液。
[实施例4](生物活性剂4的调制)
使用0.25莫尔L-抗坏血酸钠盐代替实施例1的L-抗坏血酸钾盐,再和0.25摩尔FeCl2脱水物(酐),3摩尔的MgCl2脱水物(酐)一起溶解在水中并设定为1升,再将此水溶液稀释100倍从而调制成生物活性剂4的原液。
[参考例1](生物活性剂1A的调制)
将2.5摩尔维生素C(L-抗坏血酸钾盐)溶解在已各自溶解有0.2摩尔FeCl2脱水物(酐),和3摩尔的MgCl2脱水物(酐)的水溶液中并设定为1升,再将此水溶液稀释100倍从而调制成生物活性剂1A的原液。
[参考例2](生物活性剂2A的调制)
将实施例2中调制的维生素E水性乳胶以其α-生育酚达到60摩尔的量添加在在已溶解有0.3摩尔FeSO4脱水物(酐)的水溶液中,再添加30摩尔MgCl2脱水物(酐)并用水将总量调节至1升,再将此水溶液稀释100倍从而调制成生物活性剂2A的原液。
[参考例3](生物活性剂3A的调制)
将实施例3中调制的维生素K3水性乳胶以其维生素K3达到108摩尔的量添加在已溶解有0.27摩尔FeCl2脱水物(酐)的水溶液中,再添加54摩尔MgSO4脱水物(酐)并用水将总量调节至1升,再将此水溶液稀释100倍从而调制成生物活性剂3A的原液。
[参考例4](生物活性剂4A的调制)
使用0.25莫尔L-抗坏血酸钠盐代替参考例1的L-抗坏血酸钾盐,再和0.25摩尔的FeCl2脱水物(酐),0.25摩尔的MgCl2脱水物(酐)一起溶解在水中,再在此水溶液中添加0.25摩尔L-抗坏血酸钠盐并用水将总量调节至1升,再将此水溶液稀释100倍从而调制成生物活性剂4A的原液。
[实施例5](保鲜度测试)
将制备后经过6个月的1ml的1~4,1A~4A的原液各自用水稀释1升的处理液。把比目鱼的鱼身切块浸渍在上述各自的处理液后,将鱼身切块用滤纸除去水分并用聚偏氯乙烯薄膜包起,在5℃的温度下保存。该鱼身切块保存15天后的K值(%)如表1所示为30%以下,是处于完全可以提供为生吃用的状态。
再根据表1,可以确认在溶解有二价铁盐和镁盐的水溶液中添加了维生素类的生物活性剂1A,2,3,4A比在二价铁盐中添加了维生素类后再添加镁盐的生物活性剂1,2A,3A,4发挥更显著的生物活性。
[表1]
生物活性剂 | 1 | 2 | 3 | 4 | 1A | 2A | 3A | 4A |
鱼身切块(%) | 25 | 27 | 28 | 26 | 20 | 29 | 30 | 21 |
[比较例1]
作为比较例1,使用相对FeCl2添加了等摩尔以下的维生素C以及MgCl2的处理液并进行保鲜度测试。也就是,将0.25摩尔FeCl2脱水物(酐),和0.2摩尔维生素C,和0.2摩尔MgCl2脱水物(酐)溶解在水中并设定为1升,再将此水溶液稀释100倍而成为比较原液1。将制备后经过6个月的1ml的比较原液1用水稀释成1升的比较处理液1,并和上述实施同样进行把比目鱼的鱼身切块浸渍在该比较处理液1后,将鱼身切块用滤纸除去水分,并用聚偏氯乙烯薄膜包起,在5℃的温度下保存。该鱼身切块保存15天后的K值(%)为45%,是处于只能提供勉强食用的状态。
[比较例2]
作为比较例2,使用相对FeCl2只添加了MgCl2的处理液并进行保鲜度测试。也就是,将0.25摩尔FeCl2脱水物(酐),和3摩尔MgCl2脱水物(酐)溶解在水中并设定为1升,再将此水溶液稀释100倍而成为比较原液2。将制备后经过6个月的1ml的比较原液2用水稀释成1升的比较处理液2,并和上述实施同样进行把比目鱼的鱼身切块浸渍在该比较处理液2后,将鱼身切块用滤纸除去水分,并用聚偏氯乙烯薄膜包起,在5℃的温度下保存。该鱼身切块保存15天后的K值(%)为38%,是不适合生吃用,但处于适合加热后食用的状态。
[比较例3]
作为比较例3,将浸在水中的鱼身切块进行同样的保存试验。保存15天后的K值(%)为75左右,是处于不适合食用的状态。
从以上实施例5,和比较例1以及比较例2的结果来看,可以确认FeCl2通过维生素类以及MgCl2的添加,即使保存6个月也具有充分的保鲜效果。
[实施例6]
将制备后1年的1ml的生物活性剂1~4,1A~4A的原液用水稀释并使用作处理液,并对南瓜,马铃薯,洋葱进行栽培。收获的蔬菜的各自情况如下所述。
(南瓜)
特征;使用生物活性剂1~4,1A~4A其中任何一种而栽培的南瓜,其外表具有光泽,尤其使用了生物活性剂1A,2,3,4A时,其果实丰厚并呈鲜明的桔红色,其胡萝卜素的含量是普通南瓜的2倍。
味道;干爽带甜,如表2所示其糖度为8~11高于通常的糖度(7度)。
[表2]
生物活性剂 | 1 | 2 | 3 | 4 | 1A | 2A | 3A | 4A |
糖度 | 8 | 11 | 10 | 8 | 10 | 8 | 8 | 11 |
(马铃薯)
特征;使用生物活性剂1~4,1A~4A其中任何一种而栽培的马铃薯,其表皮呈白色,尤其使用了生物活性剂1A,2,3,4A时,其表面的出芽数很少。
淀粉;如表3所示可确认为18%以上(通常为16%)。
维生素C;如表3所示可确认为32mg/100g以上(通常为23mg/100g)。
味道;任何一种在口中有柔软和膨胀之感,并有马铃薯特有的香味和浓厚的口感。并且因为涩液少而适合于做沙拉等。
[表3]
(洋葱)
特征;使用生物活性剂1~4,1A~4A其中任何一种而栽培的洋葱,其表皮有光泽,大小多很均匀。易去皮,果实结实。长时间贮存性也高。从电子显微镜照片等可确认微小的细胞都紧紧的结合在一起,是一种健全的作物。
味道;任何一种多清脆易切,生吃的口感也很好。糖度如表4所示可确认为8度以上,因大大高于通常的糖度(6度),所以清脆带甜,很适合于做沙拉等,并且在煎炒使也不容易炒烂。
[表4]
生物活性剂 | 1 | 2 | 3 | 4 | 1A | 2A | 3A | 4A |
糖度 | 8.5 | 10 | 10 | 9.0 | 10.5 | 8.7 | 9.0 | 10 |
[实施例7](药物效果)
将实施例1中所调制的生物活性剂1的原液使用作药物时,一般是适用于以下的服用法。
(1)1日3次,起床前,午饭前,睡觉前。在一杯水中(约150ml)添加下述量的生物活性剂1的原液并均匀搅拌后饮用。
(2)饮用量
饮用开始第一周;3滴×3次(1日量9滴)
饮用开始第二周;5滴×3次(1日量15滴)
饮用开始第三周;10滴×3次(1日量30滴)
饮用开始第四周;20滴×3次(1日量60滴)
(3)第五周以后饮用量
a.癌;30滴×3次(1日量90滴)
b.糖尿病,肝炎,胃溃疡,心脏病,哮喘病,高血压等;
20滴×3次(1日量60滴)
c.肾衰竭,风湿病,特应性皮炎,花粉症等;
10滴×3次(1日量30滴)
d.生理痛,便秘,醉酒,其他轻度疾病;
10滴×3次(1日量30滴)
e.健康维持;3滴×3次(1日量9滴)
根据上述饮用法给予各种疾病患者生物活性剂3时的结果如表5~表15所示。其中,任何一个表中,白检查数据的数值等,上段表示为本实施例使用前,下段为使用后。
[表5]
*1血糖值:正常值70~110ml/dl
*2HbAlc:正常值4.0~6.0%
*3中性脂肪:甘油三酯正常值50~140mg/dl
[表6]
*1血压:正常值139~101/89~61mmHg
[表7]
*1RBC:红血球数正常值350万~450万个/mm3
*2WBC:白血球数正常值4000~9000个/mm3
*3Hb:血红蛋白正常值2~15g/dl
*4Ht:血球比率正常值36~45%(成人女性)
*5BUN:尿素氮素正常值8~20mg/dl
*6CRP:正常值1.0mg/dl以下
[表8]
*1GOT:正常值5~35KU/ml
*2GPT:正常値5~25KU/ml
*3γ-GTP:正常值40单位以下(成人)
*4肿瘤标记AFP:正常值20ng/ml以下(RIA法)
[表9]
*1肿瘤标记PAP:正常值3.0ng/ml以下(RIA法)
*2肿瘤标记PSA:正常值3.0ng/ml以下(RIA法)
*3CA125:正常值50U/ml以下
*4CA19-9:正常值37U/ml以下
[表10]
*1WBC:正常值4000~9000个/mm3
*2白血球:正常值4000~9000个/mm3
*3血小板:正常值20万~40万个/mm3
*4M蛋白质:正常值1700个/mm3以下
*5CA125:正常值50U/ml以下
*6CA19-9:正常值37U/ml以下
[表11]
*1GOT:正常值5~35KU/ml
*2GPT:正常值5~25KU/ml
*3γ-GTP:正常值40单位以下(成人)
*4ZTT:正常值2~14单位
[表12]
*1CRP:正常值1.0mg/dl以下
*2RF:风湿因子正常值35U/ml以下
[表13]
*1lge-RIST:正常值280IU/ml以下
*2猫:正常值0.34UA/ml以下
*3杉树:正常值0.34UA/ml以下
*4房屋灰尘:正常值0.34UA/ml以下
*5杂草:正常值0.34UA/ml以下
[表14]
*1MRSA:正常值 阴性
[表15]
*1トリグリセライド:正常值50~140mg/dl
*2肥胖度:正常值-10~+10%
*3γ-GTP:正常值40单位以下(成人)
*4尿量:正常值500~2000ml/day
[实施例8](化妆品,护发)
将2ml生物活性剂1的原液用水稀释成1升并作为涂抹液涂抹于10名受试者的头发,每天一次,并测定洗发后所掉头发的根数。测试前平均掉发根数是7根,涂抹测试一个月后平均减少到8根。
再有,在5月份晴天时,在打高尔夫球前,对打球者得脸,头颈,手等部位涂抹上述涂抹液,打完后几乎没见到有晒黑。再有每天在脸上涂抹上述涂抹液1个月后,褐斑,雀斑减少。
[实施例9]
将2ml生物活性剂1A的原液用水稀释成1升并作为涂抹液涂抹于10名受试者的头发,每日一次,并测定洗发后所掉头发的根数。测试前平均掉发根数是11根,涂抹测试一个月后平均减少到1.5根。
[实施例10]
将2ml生物活性剂2A的原液用水稀释成1升并作为涂抹液每天涂抹于5名脸上有显著褐斑,雀斑受试者的脸,3个月后褐斑,雀斑大量减少。
本发明中,二价铁盐通过维生素C,E,K防止氧化,且增强其生物活性效果,再以镁盐使其稳定化,其结果为即使长期保存其效果也不减少,并能获得平衡的稳定效果,尤其可以用作癌症,糖尿病等疑难病的治疗药或动物及植物的发育促进剂。
Claims (5)
1.一种生物活性剂,其特征在于,其是由含有二价铁盐,和从维生素C、维生素E、维生素K中所选的一种或二种以上的维生素类,和含有镁盐的水溶液所组成;
其是在已溶解有二价铁盐和镁盐的水溶液中添加从维生素C、维生素E、维生素K中所选的一种或二种以上的维生素类;
其中,该二价铁盐和该维生素类以1∶1~1∶106摩尔比混合,该二价铁盐和该镁盐以1∶1~1∶106摩尔比混合;
所述维生素C是指L-抗坏血酸钾盐或L-抗坏血酸钠盐。
2.一种药物,其特征在于,其是含有权利要求1中所述的生物活性剂。
3.一种化妆品,其特征在于,其是含有权利要求1中所述的生物活性剂。
4.一种保鲜剂,其特征在于,其是含有权利要求1中所述的生物活性剂。
5.一种植物以及动物的发育促进剂,其特征在于,其是含有权利要求1中所述的生物活性剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-330569 | 2008-12-25 | ||
JP2008330569 | 2008-12-25 | ||
PCT/JP2009/007151 WO2010073642A1 (ja) | 2008-12-25 | 2009-12-22 | 生物活性剤、医薬、化粧品、鮮度保持剤、および植物および動物の発育促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102159222A CN102159222A (zh) | 2011-08-17 |
CN102159222B true CN102159222B (zh) | 2014-08-06 |
Family
ID=42287289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980148974.1A Active CN102159222B (zh) | 2008-12-25 | 2009-12-22 | 生物活性剂,药物,化妆品,保鲜剂,以及植物以及动物的发育促进剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110294665A1 (zh) |
EP (1) | EP2380578A4 (zh) |
JP (1) | JPWO2010073642A1 (zh) |
KR (1) | KR20110105782A (zh) |
CN (1) | CN102159222B (zh) |
WO (1) | WO2010073642A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2638913B1 (en) * | 2010-11-12 | 2016-04-06 | I.B.E. Co., Ltd. | Method for producing bioactive agent, bioactive agent produced thereby, cosmetic, freshness-maintaining agent, growth promotion agent, soil conditioning agent, and pharmaceutical stock solution |
US10765665B2 (en) * | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
IT201700085412A1 (it) * | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
JP6999175B2 (ja) * | 2018-07-31 | 2022-02-04 | 株式会社東洋新薬 | 経口組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58156539A (ja) * | 1982-03-11 | 1983-09-17 | Agency Of Ind Science & Technol | 鉄化合物水溶液の安定化方法 |
FR2715539B1 (fr) * | 1994-01-28 | 1996-02-23 | Fischer International Developm | Boisson tonique naturelle pour animaux, notamment pour chiens et pour chats. |
JPH10212477A (ja) * | 1997-01-29 | 1998-08-11 | Nippon Surfactant Kogyo Kk | O/w型エマルジョンの酸化防止方法、抗酸化剤組成物及びo/w型エマルジョン |
JP2002080376A (ja) * | 2000-06-06 | 2002-03-19 | Ibe:Kk | 生物活性剤および医薬 |
US6454971B1 (en) * | 2001-09-17 | 2002-09-24 | Tien-Te Lee | Process for producing tiles from waste material |
JP5398100B2 (ja) * | 2003-06-23 | 2014-01-29 | 大正製薬株式会社 | 鉄化合物を含む内服液剤組成物 |
CN101302487A (zh) * | 2008-07-04 | 2008-11-12 | 中国科学院微生物研究所 | 一种培育抗盐胁迫乳酸乳球菌的方法及其专用培养基 |
-
2009
- 2009-12-22 KR KR1020117014271A patent/KR20110105782A/ko not_active Application Discontinuation
- 2009-12-22 EP EP09834449.2A patent/EP2380578A4/en not_active Withdrawn
- 2009-12-22 JP JP2010543866A patent/JPWO2010073642A1/ja active Pending
- 2009-12-22 WO PCT/JP2009/007151 patent/WO2010073642A1/ja active Application Filing
- 2009-12-22 CN CN200980148974.1A patent/CN102159222B/zh active Active
- 2009-12-22 US US13/141,209 patent/US20110294665A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
JP昭58-156539A 1983.09.17 |
JP特开2002-80376A 2002.03.19 |
JP特开2005-35979A 2005.02.10 |
JP特开平10-212477A 1998.08.11 |
Also Published As
Publication number | Publication date |
---|---|
EP2380578A4 (en) | 2013-09-04 |
CN102159222A (zh) | 2011-08-17 |
KR20110105782A (ko) | 2011-09-27 |
EP2380578A1 (en) | 2011-10-26 |
US20110294665A1 (en) | 2011-12-01 |
JPWO2010073642A1 (ja) | 2012-06-07 |
WO2010073642A1 (ja) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050266052A1 (en) | Animal feed supplement for the nutritional enrichment of animal produce | |
CN101253896A (zh) | 宝石鱼油微胶囊及其制备方法 | |
CN102159222B (zh) | 生物活性剂,药物,化妆品,保鲜剂,以及植物以及动物的发育促进剂 | |
CN104585514A (zh) | 饲料添加剂,饲料和猪肉肉质改良方法 | |
Mouritsen et al. | A role for macroalgae and cephalopods in sustainable eating | |
CN104542484A (zh) | 一种富硒肉猪的饲养方法 | |
CN110604218A (zh) | 一种宠物营养膏的配方及制备方法 | |
CN106974215A (zh) | 一种预调理贝肉的加工方法 | |
CN109673966A (zh) | 一种燕麦发酵羊肉香肠工艺 | |
CN107155975A (zh) | 一种鳙鱼的防病养殖方法 | |
CN105961229A (zh) | 一种长江鲥鱼仿野生养殖技术 | |
CN105851933A (zh) | 一种保健糟鱼的制备工艺 | |
Gonda | Nutritional status of ruminants determined from excretion and concentration of metabolites in body fluids. | |
CN1433316A (zh) | 生物活性剂和药物 | |
Tarola et al. | Recent advances in the valorization of goat milk: Nutritional properties and production sustainability | |
JP5757508B2 (ja) | 生物活性剤の製造方法およびそれによって製造された生物活性剤、化粧品、鮮度保持剤、成長促進剤、土壌改良剤、および医薬用原液 | |
RU2390999C2 (ru) | Универсальный продукт питания | |
CN106721382A (zh) | 鸵鸟用饲料 | |
CN106798264A (zh) | 一种鲭鱼常温调理食品及生产工艺 | |
JP2004222599A (ja) | 調味梅干および調味梅干の製造方法 | |
CN107439772A (zh) | 一种复合胡萝卜蜜饯果 | |
CN105409811A (zh) | 一种狗咬胶胶皮及其制备方法 | |
Kolpashikov et al. | The value of trace elements in animals | |
Serventi et al. | Fat Soluble Vitamins | |
Dabrowski | Tilapia in lakes and aquaculture—ecological and nutritional approach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |